AbbVie recently announced its publication in The Lancet showing that administration of Ubrelvy (ubrogepant) during the prodrome stage of a migraine can reduce the likelihood of a migraine attack developing….
Content Section: News Posts
…60% of patients achieved a ≥50% reduction in monthly migraine days from baseline for migraine prevention, with sustained improvement in disability scores and acute medication use observed over 12 months….
Content Section: News Posts
…more expensive, drugs presents a path forward for cost-effective and accessible migraine treatment worldwide.” Robert Music, chief executive of the Migraine Trust, said: “While triptans can be highly effective for…
Content Section: News Posts
…The symptoms in the prodrome stage of migraine include fatigue, dizziness, visual aura, neck pain and sensitivity to light and sound. In the first round of treatment—which included two migraine…
Content Section: News Posts
Via Medscape: Most patients with migraine are women. This female predominance is reflected in the clinic and in clinical trials, where ~85% are women. A pharmacologist and a neurologist from…
Content Section: News Posts
…episodic migraine who have had prior failure on three or more migraine preventive treatments. Ajovy, from Teva Pharmaceuticals, is the first dedicated migraine preventive medication that will be available to…
Content Section: News Posts
…specifically designed to prevent migraine. The drug should be available for patients who experience migraine on four or more days a month and who have already failed to respond to…
Content Section: News Posts
…of migraine has been shown in many studies including Teva’s own survey of 12,545 adults with migraine – ‘Beyond Migraine’, in which 45% said migraine impacts their ability to be…
Content Section: News Posts
…Facts and Figures https://www.migrainetrust.org/about-migraine/migraine-what-is-it/facts-figures/ (figure based on current UK adult population from the Office of National Statistics – www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationestimates/articles/overviewoftheukpopulation/february2016) [Last accessed: March 2020] Buse DC. et al. ‘Chronic Migraine Prevalence,…
Content Section: News Posts
© 2024 ACNR. Published by Whitehouse Publishing. Read our Privacy and Cookie Policy. Website by Sugar Web.
Sign up to receive our email newsletter with links to the latest content. ACNR is free, thanks to the support of advertisers. The editorial content is peer reviewed and remains completely independent unless clearly specified.
For UK-based specialists, sign up for our journal mailing list.
URL here
You are now leaving the ACNR website, please click the "Continue" button below. If you do not wish to leave, please close this pop-up.
